Want to see TRDA full AI Analyst Report?

Entrada Therapeutics Inc (TRDA) Price & Analysis

160 Followers

TRDA Stock Chart & Stats

$13.99

-$0.56(-3.25%)

At close: Jan 08 4:00 PM EST

$13.99

-$0.56(-3.25%)

Day’s Range― - ―

52-Week Range$4.93 - $16.45

Previous CloseN/A

Volume35.15K

Average Volume (3M)331.85K

Market Cap

$267.47M

Enterprise Value$322.86

Total Cash (Recent Filing)$254.86M

Total Debt (Recent Filing)$49.75M

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Aug 12, 2026

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.00

Shares Outstanding38,820,618

10 Day Avg. Volume407,673

30 Day Avg. Volume331,845

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.39

Price to Sales (P/S)16.73

P/FCF Ratio-3.28

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$18.75

Price Target Upside34.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-3.91

Revenue Forecast (FY)$19.51M

Bulls Say, Bears Say

Bulls Say

Intracellular Delivery PlatformEntrada's intracellular delivery platform is a core technical moat that enables delivery of therapeutic payloads into cells for genetically defined diseases. This platform underpins multiple candidate programs, supports differentiated scientific positioning and durable partnership appeal in rare-disease modalities.

Pipeline Depth & CatalystsThe company runs five clinical-stage programs across Duchenne, DM1 and inherited retinal diseases, with multiple 2026 readouts and a Vertex-partnered DM1 program. This program breadth provides diversified value inflection points and repeated structural de-risking opportunities over the medium term.

Balance Sheet RunwayWith $254.9M in cash as of March 31, 2026 and modest leverage historically, Entrada has a multi-quarter runway into Q3 2027. That capital cushion provides durable execution flexibility to advance clinical programs and hit near-term milestones without immediate financing pressure.

Bears Say

Profitability DeteriorationThe firm swung from stronger results in 2024 to a sharp TTM deterioration: revenue fell roughly 77%, gross profit is deeply negative and net loss is about $166M. Such earnings volatility weakens operating leverage and raises the likelihood of future financing if clinical progress doesn't translate to revenue.

High Cash BurnTrailing-twelve-month operating and free cash flows are approximately -$132M, reflecting steep clinical spending. Sustained negative cash generation increases funding and dilution risk over the medium term and can force equity raises that constrain strategic optionality and extend execution timelines.

Equity Dilution RiskShareholder approval to expand the 2021 equity incentive and ESPP increases the company's ability to issue stock for compensation and financing. Given ongoing losses and burn, expanded equity capacity creates a tangible medium-term dilution risk for existing holders and future EPS recovery.

Entrada Therapeutics Inc News

Entrada Therapeutics Stockholders Approve Directors and Equity Plans

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. Entrada Therapeutics Inc. held its Annual Meeting of...

1M ago

TRDA

Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim

Guggenheim lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $20 and keeps a Buy...

1M ago

TRDA

Entrada Therapeutics Highlights Transformational Year and Pipeline Progress

The latest announcement is out from Entrada Therapeutics Inc ( ($TRDA) ). On May 18, 2026, Entrada Therapeutics...

2M ago

TRDA

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a...

2M ago

NVS

TRDA

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying...

2M ago

TRDA

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of...

2M ago

TRDA

Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst

TD Cowen analyst Joseph Thome has maintained their bullish stance on TRDA stock, giving a Buy rating today....

2M ago

TRDA

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

Reports Q1 revenue $875,000, consensus $2.92M. “With the recently announced positive data from Cohort 1 of our ELEVATE-44-201...

2M ago

TRDA

Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. On May 7, 2026, Entrada Therapeutics reported first-quarter...

2M ago

TRDA

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

Oppenheimer raised the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $21 and keeps an Outperform...

4M ago

TRDA

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Entrada is developing a cyclic cell-penetrating...

4M ago

TRDA

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Published first on TheFly – the...

4M ago

TRDA

Entrada Therapeutics management to meet with Oppenheimer

Meeting to be held on April 2 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

4M ago

TRDA

Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics

Entrada Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

5M ago

TRDA

TRDA FAQ

What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.

What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $267.47M.

When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.

How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.

Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.05.

How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,820,618 shares outstanding.

What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.

Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Entrada Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entrada Therapeutics Inc

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Entrada Therapeutics Inc (TRDA) Earnings & Revenues

Historic Earnings Reports

TRDA Stock 12 Month Forecast

Average Price Target

$18.75

▲(34.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,8.929230769230768,10.268461538461539,11.607692307692307,12.946923076923078,14.286153846153846,15.625384615384615,16.964615384615385,18.303846153846152,19.643076923076922,20.982307692307693,22.32153846153846,23.66076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,8.448461538461538,9.306923076923077,10.165384615384616,11.023846153846154,11.882307692307691,12.740769230769232,13.599230769230768,14.457692307692309,15.316153846153846,16.174615384615386,17.033076923076923,17.89153846153846,{"y":18.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,7.775384615384615,7.96076923076923,8.146153846153846,8.331538461538461,8.516923076923076,8.702307692307691,8.887692307692308,9.073076923076924,9.258461538461539,9.443846153846154,9.62923076923077,9.814615384615385,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >